Skip to main content

VibroSense Dynamics takes the first order from Finland

The Clinic for Neurophysiology at Oulu University Hospital in Finland purchases the
VibroSense Meter
® II instrument. The order includes a full license with access to all hand and foot examinations and has a total value of approximately SEK 420,000 including annual license revenue.

The total order value is divided into two parts: SEK 184,000 for the purchase and start-up of the instrument, and approximately SEK 240,000 for the license and service agreement calculated over 10 years.

Oulu University Hospital (OYS) is the northernmost of five university central hospitals in Finland. The area of responsibility at Oulu University Hospital covers the whole of northern Finland - over half of Finland's geographical area with approximately 741,000 inhabitants. The Department of Neurophysiology conducts investigations and examinations of diseases affecting the nervous system, in order to determine and rule out diagnoses, as well as choose appropriate treatments.

"With the order from Finland, we are strengthening our presence in the Nordic region. Our instrument is thus used in all the Nordic countries, i.e. Sweden, Norway, Denmark and Finland. I am both happy and enthusiastic that we are now taking the step into another market and this opens up new, exciting opportunities for our company, says Hans Wallin, CEO of VibroSense Dynamics AB.

 

Contact
Hans Wallin, CEO VibroSense Dynamics AB
Tel: +46 40 88 026
Email: info@vibrosense.com
www.vibrosense.se

“The new Gold Standard for reliable
detection of nerve damage”

About VibroSense Dynamics AB (publ)
VibroSense Dynamics AB (publ) develops and sells medical technology products and services for diagnostic support for nerve damage in the hands and feet. The method involves measuring and quantifying the ability to feel vibrations at several frequencies. The company's customers are diabetes clinics, occupational health care, hospitals, health centers and researchers.

Our vision is that the company's products should be a standard instrument in all neurological examinations to detect early signs of changes in sensation so that patients and their caregivers can implement preventive measures that prevent, reduce or delay the onset of nerve damage in the hands and feet.